June 23, 2020 / 12:41 PM / 19 days ago

BRIEF-Millendo Therapeutics Provides Corporate And Pipeline Update

June 23 (Reuters) - Millendo Therapeutics Inc:

* MILLENDO THERAPEUTICS PROVIDES CORPORATE AND PIPELINE UPDATE

* MILLENDO THERAPEUTICS-MLE-301, A SELECTIVE NEUROKININ 3 RECEPTOR (NK3R) ANTAGONIST, ADVANCING WITH FIRST-IN-HUMAN TRIALS EXPECTED TO INITIATE IN 3Q20

* MILLENDO THERAPEUTICS INC - FURTHER INVESTMENT IN NEVANIMIBE FOR CONGENITAL ADRENAL HYPERPLASIA (CAH) NOT PLANNED FOLLOWING INTERIM DATA REVIEW

* MILLENDO THERAPEUTICS INC - STRATEGIC EVALUATION IN PLACE TO DETERMINE FUTURE CORPORATE STRATEGY

* MILLENDO THERAPEUTICS INC - FINISHED Q1 2020 WITH $58.9 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below